The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
An asparaginase-based pediatric-inspired chemotherapy regimen: outcomes for older patients with Ph- ALL
|
|
| Key learnings |
|
In older patients receiving a modified pediatric-inspired chemotherapy regimen including PEG-ASP or EC-ASP, 61% of patients experienced Grade III-IV adverse events (AEs); the most prevalent AEs were thrombosis (35.6%), febrile neutropenia (38.4%), and transaminitis (34.2%). |
|
Median overall survival (OS) was 54 months (95% confidence interval (CI), > 23.7), and the leukemia-free (LFS) survival at 4 years was 48% (95% CI, 33.7–60.6). |
|
The type of ASP was not significantly associated with OS, LFS or early mortality, but AEs were higher with PEG-ASP vs EC-ASP; male sex and high PEG-ASP dose were identified as significant independent factors for thrombotic events. |
|
Older age (≥ 70 years), increased white blood cell count at presentation, previous diagnosis of malignancy, and positive measurable residual disease status post-induction therapy were found to be significantly associated with worse OS. |
|
An ASP-centered pediatric-inspired chemotherapy protocol can be an effective and well-tolerated therapeutic option for older patients with Ph- ALL when used alongside with diligent monitoring and follow-up. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content